Antikor

What Antikor does

Antikor Biopharma Ltd is a private UK biopharmaceutical company spun out of Imperial College London in 2014 via the restructuring of PhotoBiotics Limited, the original 2001 Imperial spin-out that originated the OptiLink antibody-targeting technology. The company is headquartered at the Stevenage Bioscience Catalyst on the GSK campus and operates with a small R&D team of roughly 10-15 staff across antibody discovery, bioconjugation, cell biology and synthetic chemistry.

The company's core offering is the proprietary OptiLink Fragment Drug Conjugate (FDC) platform, which uses small fully-human single-chain variable fragments (scFvs) carrying high drug loadings (high Drug:Antibody Ratio) for targeted solid tumour therapy. The platform comprises proprietary human antibody VH/VL frameworks optimised for stability and DAR, lysine-based conjugation chemistry for attaching multiple drug molecules per fragment, and tailored linker-payloads, with the FDC format intended to deliver faster tumour penetration, faster normal-tissue clearance, reduced haematological toxicities and a wider therapeutic window than conventional whole MAb-based ADCs. Named pipeline assets include ANT-045, an FDC targeting cMET, alongside a gastric cancer FDC programme; both are at the pre-clinical, IND-enabling stage.

Antikor operates a B2B business model: it is pre-revenue, monetises the OptiLink platform through technology licensing and strategic co-development alliances with pharmaceutical partners, and supplements equity capital with non-dilutive grants from Innovate UK and the EU. Its core strategic partner and lead investor is Essex Bio-Technology PLC, which provided $3.1 million in 2019 and led a ~$2.2 million follow-on in 2022, in both cases tied to gastric and solid tumour programmes. The company is currently targeting a Series A of approximately $15 million to advance products into clinical development.

Name

Antikor

Legal name

Antikor Biopharma Ltd

Website

https://antikor.co.uk

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Antikor Biopharma is a UK pre-clinical biopharmaceutical company developing next-generation Fragment Drug Conjugates (FDCs) via its proprietary OptiLink platform for solid tumour therapy, monetising the platform through licensing and co-development partnerships with pharmaceutical companies.

Ownership category

akta.pro rank

Headquarters

HQ city

Stevenage

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Licensing and Technology Partnerships: Antikor generates revenue through licensing its OptiLink technology platform to pharmaceutical companies, allowing partners to use the technology for their own ADC products. Offers flexible collaboration models where partners can extend their ADC application or patent life.
2. Strategic Alliances and Co-development Deals: Strategic partnership deals such as the 2019 Essex Bio-Technology alliance, providing funding in exchange for access to Antikor's innovative platform and future products for gastric and other solid tumours.
3. Product Development and Sale: Development of proprietary FDC product candidates (ANT-045 for cMET, gastric cancer FDCs) for potential future commercial sale or out-licensing.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Antikor is a biopharmaceutical company developing next-generation Fragment Drug Conjugates (FDCs) for solid tumour cancer therapy using its proprietary OptiLink technology platform. The platform employs small fully-human single-chain antibody fragments (scFvs) to deliver cytotoxic payloads at high drug-to-antibody ratios, enabling superior tumour penetration, fast normal-tissue clearance, and a wider therapeutic window than conventional whole monoclonal antibody ADCs. The company licenses its platform and co-develops product candidates such as ANT-045 (cMET-targeted FDC) with pharmaceutical partners.

Product overview

Antikor offers a platform-centered approach focused on its proprietary OptiLinked FDC technology for developing Fragment Drug Conjugates (FDCs). The core offering includes the OptiLinked FDC Platform, which enables the creation of next-generation antibody fragment-based drug conjugates with improved tumor penetration and therapeutic windows compared to traditional whole monoclonal antibody ADCs. Product portfolio includes ANT-045 (a novel FDC targeting cMET currently under development) alongside the company's general ADC and FDC therapeutic approaches tailored for difficult-to-treat solid tumors.

Differentiator

Problem solved

Functional benefit

Products and services

• OptiLink (OptiLinked) FDC Platform Proprietary technology platform for the development of Fragment Drug Conjugates (FDCs) using small fully-human single-chain antibody fragments (scFvs) carrying high payload loadings (high Drug-to-Antibody Ratio). Licensed to pharmaceutical and biotech partners for use in their ADC development programs.
• ANT-045 Novel Fragment Drug Conjugate candidate targeting cMET, under development by Antikor for the treatment of solid tumours including gastric cancer. Currently at the pre-clinical / IND-enabling stage.
• Fragment Drug Conjugate (FDC) Therapeutic Candidates Pipeline of next-generation Fragment Drug Conjugate product candidates using small-format antibody fragments with high DAR, designed to improve the therapeutic window for solid tumour therapy. The pipeline is developed internally and in collaboration with partners such as Essex Bio-Technology.

Quantifiable outcome

• Much wider therapeutic window than conventional ADCs demonstrated in pre-clinical data
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Stevenage Bioscience CatalystcoreStrategic or Co-development PartnerLocated at the Stevenage Bioscience Catalyst on the GSK site. Provides access to expertise and facilities enabling lean, flexible and efficient operations. Collaborates with Imperial College for research activities.
• PhotoBiotics LimitedcoreStrategic or Co-development PartnerOriginal Imperial College spin-out from which OptiLink technology was acquired. Now a subsidiary company. Antikor retains same ownership structure and constitution following 2014 restructuring.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Mersana Therapeutics: Clinical-stage ADC company developing next-generation antibody-drug conjugates with proprietary payload and linker platforms targeting solid tumors — directly comparable to Antikor's FDC platform approach.
• Heidelberg Pharma: ADC platform company using proprietary amanitin payload chemistry to build novel antibody conjugates — a direct peer given its platform-based ADC development model for solid tumors.
• Pyxis Oncology: ADC-focused oncology company developing next-generation antibody-drug conjugates against validated solid-tumor targets — comparable in modality and therapeutic focus.
• Synaffix: ADC technology platform company offering proprietary linker and payload chemistry for licensing to pharma partners — directly comparable to Antikor's licensing-oriented OptiLink FDC platform model.
• Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing next-generation immune-stimulating antibody conjugates (ISACs) for solid tumors — a peer in the broader next-gen ADC space.

Emerging players

• Tubulis: Emerging ADC platform company developing differentiated conjugates with novel linker and payload chemistry; comparable to Antikor as an early-stage platform play targeting solid tumors.
• Mythic Therapeutics: Early-to-clinical-stage ADC company focused on developing antibody-drug conjugates with engineered antibody formats for solid tumors — a peer pursuing novel antibody formats akin to Antikor's scFv approach.

Broad incumbents

• ADC Therapeutics: Commercial-stage ADC company with marketed and clinical-stage pyrrolobenzodiazepine-based antibody-drug conjugates for hematologic and solid tumors — a broader incumbent in the ADC space.
• ImmunoGen (now part of AbbVie): Pioneer in ADC technology with multiple approved and clinical-stage antibody-drug conjugates; a broad incumbent against which Antikor's next-generation FDC platform must differentiate.
• Daiichi Sankyo (Enhertu platform): Global pharmaceutical company behind Enhertu, a leading whole-MAb ADC, actively expanding next-generation ADC formats; sets the competitive bar Antikor's FDCs must surpass in solid tumors.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/antikor-biopharma-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antikor